Skip to Main Content


Skip Nav Destination

Clotting Disorders

December 20, 2021

A collection of features and news articles published in ASH Clinical News related to clotting disorders.


Coagulation Effects Differ in Knee Arthroscopy and Casting After Leg Injury

Lower-leg trauma and knee arthroscopy – both of which bring a risk of venous thromboembolism (VTE) – each affect the coagulation process differently, ...

Five-Year Follow-Up of Ruxolitinib Trial Shows Durable Clinical Results in PV Without Splenomegaly

Five-year results from the RESPONSE-2 study support the use of ruxolitinib as a second-line therapy for patients with inadequately controlled polycythemia vera (PV) without splenomegaly....

DOAC Clinics Benefit Patients and Referring Physicians

Since their introduction in 2010, direct oral anticoagulants (DOACS) have been an increasingly used therapy for patients who require anticoagulation. DOACs have advantages over warfarin ...

Rivaroxaban Possible Alternative to Heparin for VTE Prophylaxis After Laparoscopic Surgery for Colorectal Cancer

Use of rivaroxaban was superior to placebo for the extended prevention of venous thromboembolism (VTE) in patients after they underwent laparoscopic surgery for colorectal cancer, according to results from the PROLAPS-II study....

Anti-Coagulation Therapy Compliance Poor in Cancer-Associated VTE

Patients with cancer-associated venous thromboembolism (VTE) remain on anti-coagulation therapy for a short duration, but direct oral anticoagulants (DOACs) and warfarin may result in better compliance than low-molecular-weight heparin (LMWH) in these patients. ...

Rusfertide Therapy for Polycythemia Vera Leads to Sustained Hematocrit Control

Among patients with phlebotomy-dependent polycythemia vera (PV), treatment with rusfertide, a hepcidin mimetic administered weekly as a subcutaneous injection, continues to be effective, results in sustained hematocrit control, and ...

Continuation Trial Confirms Symptom Reduction With Ropeginterferon Alfa-2b Therapy for PV

Researchers confirmed ropeginterferon alfa-2b’s power to effectively reduce symptoms in patients with polycythemia vera (PV), according to study results presented by Heinz Gisslinger, MD, at the EHA 2022 Congress....

Rivaroxaban Led to Low Rates of Major Bleeding in Non-Cirrhotic Splanchnic Vein Thrombosis, May Offer Alternative to Anticoagulation

Study results suggest the oral direct factor Xa inhibitor could serve as an alternative to standard anticoagulation for the management of this manifestation of unusual site venous thromboembolism (VTE)....

You Make the Call: Would you continue anticoagulation in an elderly woman with signs of APS but inconsistent diagnostic criteria?

A 74-year-old female developed a right subsegmental pulmonary embolism (PE) three months after receiving the COVID-19 vaccine. No deep vein thrombosis (DVT) was seen on ultrasound. She was started on apixaban and ...

SARS-CoV-2 Vaccination Not Associated With a First Episode of Thrombotic Thrombocytopenia Purpura

Vaccination against SARS-CoV-2 does not appear to increase the risk of de novo immune thrombotic thrombocytopenic purpura (iTTP), according to a report published in Blood....


Connect with us:

September 2022


Close Modal

or Create an Account

Close Modal
Close Modal